Muhammad Furqan, MD, a medical oncologist and researcher at the University of Iowa Holden Comprehensive Cancer Center, presented a featured poster highlighting the Big Ten Cancer Research Consortium study BTCRC-LUN15-017 during the IASLC 2021 World Conference on Lung Cancer, held virtually Sept. 8-14.
Investigators of the single arm phase Ib/II study of pembrolizumab and Imprime PGG for patients with metastatic non-small cell lung cancer (NSCLC) after progression on first line therapy, found the combination to be safe in patients with locally advanced or metastatic NSCLC.
October 4, 2021: This month, the Big Ten Cancer Research Consortium features our member institution The Cancer Center at Illinois at University of Illinois Urbana-Champaign and Neha Gothe, MA, PhD, associate professor of kinesiology and community health at the University of Illinois Urbana-Champaign, who serves as director of the university’s Exercise Psychology Lab. She is taking her expertise in kinesiology and behavioral psychology to explore the benefits of non-traditional forms of movement, such as yoga, in cancer survivors. Read More
September 16, 2021: In this month’s Across the Consortium, we share exciting innovations developed by cancer researchers at our member institutions, including a wearable temperature sensor that can detect dangerous complications in hospitalized cancer patients and new dual-mechanism estrogen receptor inhibitors that could support the treatment of estrogen receptor-positive and metastatic breast cancers. We also share recent appointments and publications highlighting faculty at member institutions. See what’s new in this issue of Across the Consortium. Read More
September 1, 2021: This month, the Big Ten Cancer Research Consortium features our member institution Rutgers Cancer Institute of New Jersey and Coral Omene, MD, PhD, medical oncologist at Rutgers Cancer Institute and Assistant Professor of Medicine at Rutgers Robert Wood Johnson Medical School. Research Interests and Expertise: Dr. Omene is a medical oncologist with a passion for women’s health who is dedicated to the care of treating and managing a diverse pool of breast cancer patients. She has devoted much of her research toward translating novel laboratory observations into discoveries to better care for breast cancer patients, with a particular focus on triple negative breast cancer (TNBC), which is known to be among the most... Read More
September 1, 2021: While the world continues to focus on the ever-challenging worldwide COVID-19 pandemic, groundbreaking research into potentially practice-changing novel therapies for oncology patients has continued. This year has been one of innovation in unprecedented times, and the field of gastrointestinal cancers has kept pace. As an early phase clinical investigator at Rutgers Cancer Institute of New Jersey, my research focuses on developing novel combinations to treat advanced biliary tract, hepatic, and pancreatic cancers. Unfortunately, the rising incidence of hepatobiliary and pancreatic cancers, coupled with poor outcomes for these patients, continues to be a pressing reminder of our mission as researchers. Read More
August 26, 2021: In this month’s Across the Consortium, cancer investigators, program managers, and administrators share their progress in oncology research and maintaining their excellent standing through NCI-designation and association accreditation. Learn about new tools that may help identify patients who are at high risk of cancer progression and relapse, as well as promising pre-clinical results to treat human estrogen-receptor positive breast cancer and their metastases in bone, brain, liver, and lungs. Also, find out which of our Big Ten Cancer Research Consortium members increased clinical trial enrollment by 167 percent, and minority participation in clinical trials to 56 percent of total enrollment. Read on to discover what’s new across the Big Ten Cancer Research Consortium. Read More
August 24, 2021: Robert Wesolowski, MD, associate professor at The Ohio State University College of Medicine, was recently appointed as co-chair of the Big Ten Cancer Research Consortium’s Correlative Sciences Clinical Trial Working Group (CTWG). He joins fellow co-chair Thomas G. Sors, PhD, Assistant Director of the Purdue Institute of Inflammation, Immunology and Infectious Disease. The group serves as a resource to advise investigators on the correlative aspects of Big Ten CRC studies in development. “As a clinical trialist, this appointment fits my research interests,” said Dr. Wesolowski, a breast cancer medical oncologist at The Ohio State... Read More
August 17, 2021: Patrick C. Ma, MD, MSc, a professor at Penn State College of Medicine and a medical oncologist specializing in thoracic oncology at Penn State Cancer Institute, has been appointed to represent Penn State Cancer Institute on the Big Ten Cancer Research Consortium Steering Committee. The Steering Committee is composed of one researcher from each Big Ten CRC member institution and meets regularly to review activities of the consortium and decide matters of policy. The Steering Committee determines the criteria for approving concepts for development with the Big Ten CRC. Read More
August 6, 2021:by Vijaya Bhatt, MBBS, MS Vijaya Bhatt, MBBS, MS, is an associate professor in the University of Nebraska Medical Center Division of Oncology/Hematology, Department of Internal Medicine, College of Medicine, and medical director of the Leukemia Program at UNMC.With the aging US population, we face the challenge of rising incidence of cancer in older adults. Older adults are at a higher risk of developing and dying from cancers. Several factors contribute to poor outcomes including cancer biology, multimorbidity, frailty, and social isolation, which has become worse during the COVID-19 pandemic. Older adults are also frequently not well represented in clinical trials; this poses additional challenges by creating a knowledge gap in understanding how to optimally treat older adults with comorbidities.... Read More
August 3, 2021: Purdue Center for Cancer Research (PCCR) scientist Philip Low, PhD, Presidential Scholar for Drug Discovery and Ralph C. Corley Distinguished Professor of Chemistry - Biochemistry (Department of Chemistry) at Purdue University. The latest research update from Dr. Low is the design, synthesis, and patenting of PSMA-617, an investigational PSMA-targeted radioligand therapy for metastatic castration-resistant prostate cancer. It began with a PCCR collaboration including Dr. Low, Timothy Ratliff, PhD, and Tom Gardner, MD, from Indiana University School of Medicine, who ran the first clinical imaging trial, funded by PCCR, to show the targeting agent was highly prostate cancer specific. Read More
Subscribe to the Big Ten CRC Newsletter
X
Facebook
YouTube